Navigation Links
LSUHSC research discovers new drug target for metastatic breast cancer
Date:4/11/2013

New Orleans, LA Research led by Dr. Suresh Alahari, Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, is the first to report that two specific tumor suppressor genes work in concert to inhibit the growth and spread of breast tumor cells to the lungs. The research is published this week online in the Journal of Biological Chemistry.

Working in a mouse model, the LSUHSC research team studied LKB1, an enzyme that functions as a tumor suppressor in the small intestine, and Nischarin, a novel protein that regulates breast cancer cell migration and movement discovered by Dr. Alahari in 2000. Thirty percent of lung adenocarcinomas have an LKB1 gene mutation, and high levels of the LKB1 protein in breast cancer cells have been shown to significantly inhibit tumor growth. The LKB1-interacting protein is also structurally similar to Nischarin. The researchers suspected that the two suppressors might relate to each other, and they did in fact discover a functional and biochemical link between them.

The researchers demonstrated that Nischarin and LKB1 regulate breast cancer cell migration, anchorage-independent growth, tumor growth, and metastasis. They also identified a new pathway by which LKB1 suppresses tumor cell movement.

Metastasis, a complex process involving cell growth, tumor cell migration, and invasion is a leading cause of cancer-related deaths. Therefore, it is important to identify the molecular targets that can prevent cancer metastasis.

"The molecular mechanisms of tumor suppressor genes are not clearly understood, and each discovery moves us another step closer to a treatment advance or cure," notes Dr. Alahari.

Excluding skin cancer, breast cancer is the most common type of cancer among women in the United States. The American Cancer Society estimates 232,340 new cases of invasive breast cancer among American women this year, and 2,240 among men in the US, with 39,620 deaths in women and 410 deaths in men.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
2. LSUHSC research finds treating stress prevented new MS brain lesions
3. LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS
4. LSUHSC research identifies new therapeutic target for Alzheimers disease
5. LSUHSCs Weiss chosen to help set national eye policy, research
6. LSUHSC research discovery provides therapeutic target for ALS
7. LSUHSC scientist awarded nearly $2 million to determine role of biofilms in common fungal infection
8. LSUHSC research identifies co-factors critical to PTSD development
9. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
10. Research reveals first evidence of hunting by prehistoric Ohioans
11. Diabetes Research Institute develops oxygen-generating biomaterial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology: